
LAVA Therapeutics NV
NASDAQ:LVTX

LAVA Therapeutics NV
Net Issuance of Debt
LAVA Therapeutics NV
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
LAVA Therapeutics NV
NASDAQ:LVTX
|
Net Issuance of Debt
-$571k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Pharming Group NV
AEX:PHARM
|
Net Issuance of Debt
-$34.4m
|
CAGR 3-Years
-120%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-48%
|
|
![]() |
ProQR Therapeutics NV
NASDAQ:PRQR
|
Net Issuance of Debt
-€1.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Uniqure NV
NASDAQ:QURE
|
Net Issuance of Debt
-$53.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
argenx SE
XBRU:ARGX
|
Net Issuance of Debt
-$5.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
![]() |
Merus NV
NASDAQ:MRUS
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

See Also
What is LAVA Therapeutics NV's Net Issuance of Debt?
Net Issuance of Debt
-571k
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Net Issuance of Debt amounts to -571k USD.